Agenus CEO Discusses Manufacturing Deal with Zydus, France's AAC Expansion, and Phase 3 BATMAN Trial in MSS Colorectal Cancer
ByAinvest
Wednesday, Jan 28, 2026 8:09 pm ET1min read
AGEN--
Agenus has closed a manufacturing collaboration with Zydus Lifesciences, expanded France's reimbursed early access pathway, and is preparing for a global phase 3 trial in MSS metastatic colorectal cancer. The collaboration includes the sale of Agenus' biologics facility in California and an equity sale at a significant premium to market price. The deal strengthens Agenus' ability to execute its strategy by providing capital and long-term U.S.-based biologics manufacturing capacity.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet